Atherosclerotic Cardiovascular Disease Beginning in Childhood

Young Mi Hong, MD
Department of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Korea

ABSTRACT

Although the clinical manifestations of cardiovascular disease (CVD), such as myocardial infarction, stroke, and peripheral vascular disease, appear from middle age, the process of atherosclerosis can begin early in childhood. The early stage and progression of atherosclerosis in youth are influenced by risk factors that include obesity, hypertension, dyslipidemia, and smoking, and by the presence of specific diseases, such as diabetes mellitus and Kawasaki disease (KD). The existing evidence indicates that primary prevention of atherosclerotic disease should begin in childhood. Identification of children at risk for atherosclerosis may allow early intervention to decrease the atherosclerotic process, thereby preventing or delaying CVD. This review will describe the origin and progression of atherosclerosis in childhood, and the identification and management of known risk factors for atherosclerotic CVD in children and young adults. (Korean Circ J 2010;40:1-9)

KEY WORDS: Atherosclerosis; Cardiovascular diseases; Child; Adolescent; Primary prevention.

Introduction

Although atherosclerosis manifests clinically in middle and late adulthood, it is well-known that it has a long asymptomatic phase of development, which begins early in life, often during childhood. In most children, atherosclerotic vascular changes are minor and can be minimized or prevented with a healthy lifestyle. However, in some children the process is accelerated because of risk factors or specific diseases. Identification of children who are at risk for atherosclerosis may allow early intervention to decrease the atherosclerotic process, preventing or delaying cardiovascular diseases (CVD), such as myocardial infarction, stroke, and peripheral vascular disease.

Atherosclerotic Changes in Childhood

Atherosclerosis begins in childhood as an accumulation of fatty streaks—lipid-engorged macrophages (foam cells) and T lymphocytes in the intima of the arteries. Fatty streaks may or may not progress, and may regress. In some people, lipid accumulation is more pronounced with time, and the accumulated lipid becomes covered by a fibromuscular cap to form what is termed a fibrous plaque. Temporally, between the fatty streak and the fibrous plaque, transitional stages of atherosclerosis exist that are not identifiable by gross examination alone. With time, fibrous plaques enlarge and undergo calcification, hemorrhage, ulceration or rupture, and thrombosis. Thrombotic occlusion precipitates clinical disease such as myocardial infarction, stroke, or gangrene depending on which artery is affected (Fig. 1).1)

As detailed below, autopsy studies in children and young adults who had died of non-cardiovascular causes have conclusively demonstrated early development of atherosclerosis.

Attention was first drawn to the early origin of atherosclerosis by an autopsy study conducted on young soldiers killed in the Korean War.2) Their average age was 22 years, and over 70% of them had evidence of atherosclerosis in their coronary arteries. Postmortem coronary angiography and dissection of hearts from 105 United States soldiers killed in Vietnam demonstrated that 45% had some evidence of atherosclerosis and 5% had gross evidence of severe coronary atherosclerosis.3) Another study demonstrated a very high incidence of lipid-laden macrophages in the intima of the aorta and coronary arteries of young American
children killed in motor accidents, with over 50% of children aged 10-14 years having some evidence of early atherosclerosis. A nation-wide autopsy-based study of atherosclerosis in young Japanese (1 month-39 years) disclosed the presence of fatty streaks in 29% of aortas in those aged <1 year and in 3.1% of coronary arteries of children aged 1-9 years. Another examination 13 years later revealed an increased prevalence and extent of coronary artery lesions in autopsied subjects who died in their third and fourth decade of life. In the Bogalusa Heart Study, the extent of fatty streaks and fibrous plaques in the aorta and coronary arteries were examined in 204 young patients 2-39-years-of-age. The prevalence of fatty streaks in the coronary arteries increased with age from approximately 50% at 2-15-years-of-age to 85% at 21-39-years-of-age, and the prevalence of raised fibrous-plaque lesions increased with age from 8% at 2-15-years-of-age to 69% at 26-39-years-of-age. The prevalence and the extent of atherosclerosis was greater with increasing age, body mass index (BMI), blood pressure, and levels of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). The degree of involvement increased with worsening severity and greater numbers of risk factors. In the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study, the right coronary arteries and aortas were examined during autopsy in 2,876 individuals aged 15-34 years. Raised fatty streaks were present in the abdominal aortas of approximately 20% of those aged 15-19 years and approximately 40% of subjects 30-34-years-of-age, and in the right coronary arteries of approximately 10% of 15-19-year-old subjects and approxima-

tely 30% of those aged 30-34 years at the time of death. The percent of intimal surface involved with raised fatty streaks increased with age and was associated with a high level of non-high-density lipoprotein cholesterol (HDL-C) and low HDL-C, hypertension, obesity, and impaired glucose tolerance. An intravascular ultrasound study determined that 17% of otherwise healthy heart donors <20 years of age, 37% of those aged 20-29 years, 60% of those aged 30-39 years, 71% of those aged 40-49 years, and 85% of those ≥50-years-of-age had evidence of coronary atherosclerosis.

**Noninvasive Assessment of Preclinical Atherosclerosis**

Until recently, our understanding of the childhood antecedents of adult CVD was limited mainly to autopsy studies and pathologic findings in teenagers and young adults who died from accidental causes. Recent advances in noninvasive techniques have allowed detection of early changes in physiology and visualization of anatomical and mechanical abnormalities that reflect the preclinical biology of atherogenesis.

In adults, noninvasive measures of atherosclerosis have become established as valid and reliable tools for refining the cardiovascular risk to target individuals who need early intervention. Noninvasive ultrasound studies of the neonatal aorta and fetal early childhood postmortem studies indicate that impaired fetal growth, in utero exposure to maternal hypercholesterolemia, and diabetic macrosomia may all be important risk factors for vascular changes consistent with the earliest physical signs of atherosclerosis. With limited pediatric data, the use of these techniques in children and adolescents largely has been reserved for research purposes.

**Functional measures**

Endocardial function can be evaluated by measuring changes in blood vessel diameter in response to specific stimuli using the technique of flow-mediated dilatation (FMD). FMD measures the nitric oxide-mediated vasodilation produced by increased flow after a period of ischemia (e.g., ischemia induced by an inflated blood pressure cuff) by brachial artery ultrasonography. Abnormalities in endothelial function have been noted in children affected with a variety of conditions. Decreased FMD has been observed in children with type 1 diabetes mellitus, a family history of premature coronary disease, and Kawasaki disease (KD).

**Structural measures**

Carotid intima-media thickness (cIMT) has been used extensively in children and young adults with risk factors for CVD. Several large studies have shown that increased IMT correlates well with traditional cardiovascular
cicular risk factors that include excess weight, dyslipidemia, and hypertension. In addition, increased IMT is found in adolescents with familial hyperlipidemia and in children with a parent with a history of premature myocardial infarction. Young adults with increased IMT have an increased likelihood of a cardiovascular event that includes myocardial infarction and stroke.

In addition to cIMT, some pediatric studies have measured IMT in the aorta (aIMT). This technique has proved useful even in neonates and young children. Increased aortic wall thickness has been associated with low birth weight, intrauterine growth restriction, maternal smoking, and familial hypercholesterolemia.

The combined thickness of carotid artery intima and media is associated with coronary heart disease risk factors. The intima is more directly involved in atherosclerosis than the media, and the thickness of the intima alone measured by high-resolution ultrasonography may aid in detecting early vascular changes of atherosclerosis.

Serum LDL-C level may be more closely associated with the carotid intimal thickness than IMT for patients with coronary atherosclerosis.

Arterial stiffness can be assessed noninvasively by measuring a parameter known as the pulse wave velocity (PWV) between two major arteries located in the upper body (i.e., carotid or brachial artery) and the lower body (i.e., femoral or ankle). PWV reflects the time needed for the pulse wave to travel a given distance along the blood vessel. Stiffer arteries produce a higher PWV.

Arterial stiffness normally varies among adolescents and young adults based upon gender, age, and ethnicity. After adjusting for age and gender, arterial stiffness in adolescents and young adults is associated with CVD risk factors that include BMI, hypertension, and elevations in serum triglyceride (TG), homocysteine, and fasting insulin concentrations.

PWV may have an advantage compared to other noninvasive techniques in the primary care setting due to its simplicity of use and shorter time required for a measurement.

Computed tomography (CT) allows localization and quantification of calcium deposits in coronary arteries. However, the paucity of data regarding calcification in early atherogenesis, and the potentially harmful effects of early radiation exposure currently limits the clinical use of CT in children.

Magnetic resonance imaging (MRI) is increasing being used to assess early atherosclerosis, since it allows characterization of cardiovascular structure, function, and blood flow without exposure to ionizing radiation. It has been used to measure atheromatous plaques and characterize structure in the peripheral circulation.

Both CT and MRI are currently being combined with positron emission tomography and fluorescent imaging to evaluate plaque biology in more detail.

### Risk Factors for Atherosclerosis in Children

In adults, large prospective population-based studies have shown that a higher risk of CVD is associated with multiple risk factors that include obesity, hypertension, dyslipidemia, diabetes, smoking, and family history of CVD. While data linking these risk factors to cardiovascular events are limited in children, these risk factors are associated with acceleration of atherosclerosis in children. These risk factors do not generally occur in isolation but are usually found concurrently.

### Overweight/Obesity

The prevalence of children who are clinical overweight or obese is increasing rapidly globally. Children and adolescents who are overweight/obese are more likely to be overweight/obese as adults. In autopsy studies, BMI was positively correlated with more extensive atherosclerotic changes in the aorta and coronary arteries during childhood.

Childhood obesity raises the risk of other risk factors that are associated with heart disease in early adulthood, such as high blood pressure or diabetes mellitus. In one study, children between the ages of 6 and 19 years with metabolic syndrome showed an increased risk of CVD (odds ratio: 14.6, 95% confidence interval: 2.8-45.3) at 25 year follow-up compared to the general school population. Generally, overweight children are inactive and may have obstructive sleep apnea, both of which are associated with CVD in adults.

### Hypertension

Children and adolescents with hypertension are more likely to have hypertension as adults. In adults, hypertension is a well-established risk factor for CVD that include myocardial infarction and stroke. Although similar direct evidence linking hypertension with CVD is lacking, hypertension has been linked to increased IMT and arterial stiffness, suggestive of accelerated atherosclerosis.

### Dyslipidemia

Dyslipidemia is a disorder of lipoprotein metabolism that results in increased TC, high LDL-C, low HDL-C, and high TG. The National Cholesterol Education Program (NCEP) defines dyslipidemia in children as values that are greater than the 95th percentile and defined cutoff points. Subsequently, the National Health and Nutrition Examination Surveys (NHANES) presented age- and gender-specific lipoprotein threshold concentrations for adolescents. The predictive capacity of both NCEP and NHANES cut points were similar predicting high common carotid artery IMT in adulthood. Adolescent lipid levels were more strongly associated
with high IMT in adulthood than change in lipid levels. Overweight or obese adolescents with dyslipidemia had increased cIMT in adulthood compared with those who did not have both risk factors, leading the authors to suggest that dyslipidemia screening could be limited to overweight or obese adolescents.

Although dyslipidemia is an established risk factor for CVD in adults, no long-term studies directly link dyslipidemia in childhood with subsequent CVD, with the possible exception of children with monogenetic causes of dyslipidemia such as familial hypercholesterolemia. Autopsy studies demonstrated an increase atherosclerotic lesions in the coronary artery and aorta with increasing serum LDL-C and decreasing HDL-C.7)8) In individuals who displayed elevations in non-HDL-C, LDL-C, and TC: HDL-C in children are more likely to have increased IMT in adulthood.33)

Family history
A family history of CVD is an independent risk factor for coronary vascular events, especially in young adults. Children whose parents or grandparents had a heart attack or stroke at an early age have twice the risk of developing CVD in middle-aged adults.34) Healthy offsprings of parental history of premature acute myocardial infarction can present with lipid disturbances and increased carotid IMT compared to healthy children with no parental history of coronary disease.35)

Smoking
Smoking and passive exposure to tobacco smoke increases the risk of CVD. Teenagers who smoke are likely to continue smoking into adulthood, thus increasing their risk of early CVD. Smoking is associated with a much greater extent of fatty streaks and raised lesions in the abdominal aorta.36) Although the mechanisms in cigarette smoking-related cardiovascular dysfunction are largely unknown, smoking increases inflammation, thrombosis, and oxidation of LDL-C. Recent experimental and clinical data support the hypothesis that cigarette smoking exposure increases oxidative stress as a potential mechanism for initiating cardiovascular dysfunction.37)

Hyperglycemia
Hyperglycemia is strongly associated with the extent of fatty streaks and raised lesions in both the coronary artery and the abdominal aorta.38) Increased IMT has been documented in children with type 1 diabetes.39) survivors from childhood cancer, and congenital heart disease. The American Heart Association has issued recommendations for cardiovascular risk management in these high-risk diseases.40)

Risk Assessment
In adults without known CVD, a multivariable assessment is used to estimate their risk for cardiovascular events and to guide therapeutic choices aimed at risk reduction (Framingham Risk Score). No such system is used in clinical pediatric practice. As described

Table 1. PDAY risk score for predicting advanced atherosclerotic lesions in coronary arteries

| Risk factors | Coronary Artery Risk Scores |
|--------------|---------------------------|
| Immutable risk factors | | |
| Age (years) | | |
| 15-19 | 0 |
| 20-24 | 5 |
| 25-29 | 10 |
| 30-34 | 15 |
| Sex | | |
| Male | 0 |
| Female | -1 |
| Modifiable risk factors | | |
| Non-HDL-C (mg/dL) | | |
| <130 | 0 |
| 130-159 | 2 |
| 160-189 | 4 |
| 190-219 | 6 |
| ≥220 | 8 |
| HDL-C (mg/dL) | | |
| <40 | 1 |
| 40-59 | 0 |
| ≥60 | -1 |
| Smoking | | |
| Nonsmoker | 0 |
| Smoker | 1 |
| Blood pressure | | |
| Normotensive | 0 |
| Hypertensive | 4 |
| Obesity (BMI) | | |
| Men | | |
| BMI ≤ 30 kg/m² | 0 |
| BMI >30 kg/m² | 6 |
| Women | | |
| BMI ≤ 30 kg/m² | 0 |
| BMI >30 kg/m² | 0 |
| Hyperglycemia | | |
| Glycohemoglobin <8% | 0 |
| Glycohemoglobin ≥8% | 5 |

Adapted from McMahan et al.43) PDAY: Pathobiological Determinants of Atherosclerosis in Youth, HDL-C: high-density lipoprotein cholesterol, BMI: body mass index
below, a grading system has been proposed based on data from the PDAY study.42)43)

Pathobiological Determinants of Atherosclerosis in Youth Risk Scores

The PDAY study of autopsy findings in young people developed a risk score that provides a simple way to calculate weighted effects of the major established risk factors on atherosclerosis (Table 1). Risk scores computed from the modifiable risk factors were associated with prevalence of microscopically demonstrable lesions of atherosclerosis and with the extent of the earliest detectable gross lesion (fatty streaks) in the coronary artery and aorta. When tested in young persons in the Coronary Artery Risk Development in Youth Adults (CARDIA) study, this risk score predicted calcium in the coronary arteries as long as 15 years after the risk factors were measured.44)

The severity of childhood atherosclerosis increases as the number of CVD risk factors. Children with one or more known atherosclerotic risk factors should be screened for additional risk factors. Fig. 2 shows the estimated probability of advanced atherosclerotic lesions in the coronary arteries by the PDAY modifiable risk score (5-year age group for men and women).43)

Screening Tests

Screening every child with tests to look for atherosclerosis risk factors is not currently recommended. The most current recommendation is to screen children and adolescents who have one or more of the following risks:

- Family history of early CVD (before age 55 for men and 65 for women), high cholesterol, high lipids, or diabetes
- Overweight/obesity, hypertension, dyslipidemia, and insulin resistance
- High-risk diseases (as summarized above)

The first screening should take place after 2 years of age but no later than 10 years of age. The following screening items should be included:

| Table 2. Guidelines for diet, smoking and physical activity for children

Diet
- Balance calorie intake and physical activity to achieve or maintain a healthy body weight
- Consume a diet rich in vegetables and fruits
- Choose whole-grain, high-fiber foods
- Consume fish, especially oily fish, at least twice a week (omega-3 fatty acids)
- Limit your intake of saturated fats to <7% of energy, cholesterol to <300 mg per day, and trans fat to <1% of energy
- Minimize intake of beverages and foods with added sugars
- Choose and prepare foods little or no salts (sodium intake <2.3 g/d)
- If you consume alcohol, do so in moderation

Smoking
- Question tobacco use by parents at every visit
- Question tobacco use by children at every visit starting at age 10
- Advise avoidance of second-hand smoke at home, with friends, at school, or at work

Physical activity
- Advise young people to participate in at least 60 minutes of moderate to vigorous physical activity every day
- Physical activity should be fun for children and adolescents
- For adolescents, resistance training (10-15 repetitions at moderate intensity) can be combined with aerobic activity in an overall activity program
- Sedentary time should be limited. For example, limit television time to at most 2 hours per day

Fig. 2. Estimated probability of advanced atherosclerotic lesions in the coronary arteries by PDAY risk scores. PDAY: Pathobiological Determinants of Atherosclerosis in Youth.
• Blood pressure (on three separate occasions)
• Calculation of BMI
• Fasting lipid profile
• Fasting blood sugar
• Exercise, diet, and sleep
• History of smoking and smoke exposure

Primary Prevention of Atherosclerotic Cardiovascular Disease in Childhood

The existing evidence indicates that primary prevention of atherosclerotic CVD should begin in childhood. It would be most effective to control risk factors early in life. The following guidelines are based on the recommendations by the American Heart Association (AHA).40)41)45

Table 3. Guidelines for cardiovascular risk reduction in children and adolescents with identified risk

| Dyslipidemia                      |
|----------------------------------|
| **Definition**                   |
| TC >200 mg/dL (5.18 mmol/L)      |
| LDL-C >130 mg/L (3.36 mmol/L)    |
| HDL-C <40-45 mg/dL (1.0 mmol/L)  |
| TG >150 mg/dL (1.7 mmol/L) in adolescents, >130 mg/dL (1.47 mmol/L) in younger children |

| Nonpharmacologic therapy         |
| --------------------------------|
| Dietary intervention and increased activity at least for 6-12 months, then repeat LDL measurement |

| Pharmacologic therapy            |
|----------------------------------|
| If nonpharmacologic therapy does not decrease cholesterol levels sufficiently after 6-12 months, or if a child’s cholesterol or TG levels are high, one or more medication may be recommended |

Hypertension

| Definition                     |
|--------------------------------|
| Hypertension: >95th percentile |
| Prehypertension: 90-95th percentile |

Nonpharmacologic therapy

| Diet and increased activity |
|----------------------------|
| Reduce sodium in the diet  |
| Increased fruits and vegetables |
| Evaluate for secondary causes (e.g., renal diseases, coarctation of aorta) |

Pharmacologic therapy

| If the BP persists above the targeted goal despite nonpharmacologic therapy: antihypertensive medication started |
| For children with severe hypertension (5 mmHg greater than the 99th percentile) and those with hypertensive target-organ damage (e.g., left ventricular hypertrophy) or high risk diseases (Table 2) with blood pressure above the 95th percentile: pharmacologic therapy started. |

Overweight or obesity

| Definition                 |
|----------------------------|
| Overweight: BMI >85th percentile |
| Obesity: >95th percentile |

Treatment

| Lifestyle changes |
|-------------------|
| Nutrition education: diet, weight follow-up every 2-4 weeks for 6 months |
| Activity counseling |
| If BMI still elevated, weight management program |
| Match energy needs for normal growth and development |
| Maintain weight or slow rate of weight gain for younger children to achieve healthy BMI with growth in height |
| Gradual weight loss (1-2 kg/mo) in overweight adolescents or in very overweight younger children or in those with co-morbid conditions |

Insulin resistance and diabetes mellitus

| Insulin resistance     |
|-----------------------|
| Fasting glucose=100-126 mg/dL: calorie-reduced diet, increased activity aimed at 5-10% decrease in weight over 6 months |
| If repeated fasting glucose=100-126 mg/dL: insulin-sensitizing medication as prescribed by an endocrinologist |

| Diabetes mellitus     |
|-----------------------|
| Casual glucose>200 mg/dL or fasting glucose>126 mg/dL: endocrine referral for evaluation and management |
| Maintain glycated hemoglobin <7% |

TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, TG: triglyceride, BP: blood pressure, BMI: body mass index
Management of Children and Adolescents With High-Risk Diseases

Certain pediatric disease states are associated with dramatically accelerated atherosclerosis, with clinical coronary events occurring in childhood or very early adult life. Intensive cardiovascular risk reduction is of critical importance in such children. The AHA developed recommendations for cardiovascular risk management in high-risk pediatric settings. The recommen-

Table 4. Disease stratification by risk

| Risk category | Rationale | Disease process/Condition |
|---------------|-----------|---------------------------|
| Tier I        | High risk | Manifest CAD <30 years of age: clinical evidence |
|               |           | Homozygous familial hypercholesterolemia (FH) |
|               |           | Diabetes mellitus, type 1 |
|               |           | Chronic kidney disease (CKD)/end-stage renal disease (ESRD) |
|               |           | Post-orthotopic heart transplantation (OHT) |
|               |           | Kawasaki disease, current coronary aneurysms |
| Tier II       | Moderate risk | Accelerated atherosclerosis: pathophysiological evidence |
|               |           | Heterozygous FH |
|               |           | Kawasaki disease with regressed coronary artery aneurysms |
|               |           | Diabetes mellitus, type 2 |
|               |           | Chronic inflammatory disease |
| Tier III      | At risk | High-risk for accelerated atherosclerosis: epidemiological evidence |
|               |           | Post-cancer treatment |
|               |           | Congenital heart disease |
|               |           | Kawasaki disease without detected coronary involvement |

Table 3.45(46)

Yes No Yes No

Fig. 3. Risk-stratification and treatment algorithm for high-risk pediatric populations. Detailed informations on the treatment recommendations are available at Ref.40(41) Step 4-for tier I, initial management is therapeutic lifestyle change plus disease-specific management, while for tiers II and III, initial management is therapeutic lifestyle change; Step 5-for tiers II and III, if goals are not met after initial management, consider medication. FH: familial hypercholesterolemia, ESRD: end-stage renal disease, CV: cardiovascular, CAD: coronary artery disease, BP: blood pressure, LDL: low-density lipoprotein, FG: fasting glucose, HgbA1c: hemoglobin A1c, ht: height, pt: patient.
dations were peer reviewed and then endorsed by the American Academy of Pediatrics. As summarized in Table 4, the eight identified diseases or states have been categorized in three risk tiers (“high”, “moderate”, “at risk”) based upon risk for CVD.

For children at the highest risk (tier I), the intervention strategy regards the diagnosis as a “coronary heart disease equivalent” with recommendations for risk reduction similar to secondary prevention guidelines for adults with established coronary disease. For tier II, complete risk factor assessment is recommended with specific defined therapeutic goals. For children with diagnoses in tier III, the focus is on complete risk factor assessment with therapeutic goals as defined for children in general.

Recommendations for evaluation and treatment are summarized in the following treatment algorithm (Fig. 3).

REFERENCES

1. McGill HC Jr, McMahan CA, Herderick EE, Malecom GT, Tracy RE, Strong IP. Origin of atherosclerosis in childhood and adolescence. J Clin Nutr 2000;72(5 Suppl):1307S-155.
2. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea: preliminary report. J Am Med Assoc 1953;152:1090-3.
3. McNamara JJ, Molot MA, Strempel JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA 1971;216:1185-7.
4. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries in children and young adults. Arteriosclerosis 1988;9(Suppl 1):119-32.
5. Tanaka K, Masuda J, Imamura T, et al. A nation-wide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis 1988;72:143-56.
6. Imakita M, Yutani C, Strong IP, et al. Second nation-wide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis 2001;155:487-97.
7. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-6.
8. McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000;20:1998-2004.
9. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001;103:2705-10.
10. Skilton MR. Intrauterine risk factors for precocious atherosclerosis. Pediatrics 2008;121:570-4.
11. Urbina EM, Williams RV, Alpert BS, et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009;54:919-50.
12. Gaeta G, De Michele M, Cuomo S, et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction.
mia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns Study, the Bogalusa Heart Study, and the CDAH (Childhood Determinants of Adult Health) Study. J Am Coll Cardiol 2009;53:860-9.

33) Frontin MG, Srinivasan SR, Xu J, Tang R, Bond MG, Berenson GS. Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study. Pediatrics 2008;121:924-9.

34) Lloyd-Jones DM, Nam BH, D’Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004;291:2204-11.

35) Cuomo S, Guarini P, Gaeta G, et al. Increased carotid intima-media thickness in children-adolescents, and young adults with a parental history of premature myocardial infarction. Eur Heart J 2002;23:1345-50.

36) McGill HC Jr, McMahan CA, Zieske AW, Malcom GT, Tracy RE, Strong JP. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 2001;103:1546-50.

37) Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731-7.

38) McGill HC Jr, McMahan CA, Malcom GT, Oalman MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol 1995;15:431-40.

39) Järvisalo MJ, Putto-Laurila A, Jartti L, et al. Carotid artery intima-media thickness in children with type I diabetes. Diabetes 2002;51:493-8.

40) Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science: the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease- and the Interdisciplinary Working Group on Quality of Care and Outcomes Research- endorsed by the American Academy of Pediatrics. Circulation 2006;114:2710-38.

41) American Academy of Pediatrics. Cardiovascular risk reduction in high-risk pediatric populations. Pediatrics 2007;119:618-21.

42) McMahan CA, Gidding SS, Fayad ZA, et al. Risk scores predict atherosclerotic lesions in young people. Arch Intern Med 2005;165:883-90.

43) McMahan CA, Gidding SS, Malcom GT, Tracy RE, Strong JP, McGill HC Jr. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics 2006;118:1447-53.

44) Gidding SS, McMahan CA, McGill, et al. Prediction of coronary artery calcium in young adults using the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) risk score. Arch Intern Med 2006;166:2341-7.

45) Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003;107:1562-6.

46) Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association Pediatric and Adult Nutrition Guidelines. A Scientific Statement From the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 2009;119:1161-75.

47) McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study. Circulation 2008;117:1216-27.